CellaVision — AGM Information 2022

May 11, 2022

Bulletin from the Annual General Meeting of CellaVision AB (publ)

The following resolutions were passed at the Annual General Meeting (the "AGM") of CellaVision AB (publ) ("CellaVision") on 11 May 2022 in Lund.

Adoption of profit and loss account and balance sheet and discharge from liability

The AGM resolved to adopt the profit and loss account and the balance sheet as well as the consolidated profit and loss account and the consolidated balance sheet for the financial year 2021. Furthermore, the members of the Board of Directors and the Managing Director were discharged from liability for the financial year 2021.

Allocation of profit

The AGM resolved, in accordance with the Board of Directors' proposal, on a dividend of SEK 2 per share with record date on 13 May 2022. The dividend is expected to be paid by Euroclear Sweden AB on 18 May 2022.

Board of Directors and auditor

The AGM resolved, in accordance with the Nomination committee's proposal, on re-election of Mikael Worning, Christer Fåhraeus, Åsa Hedin and Stefan Wolf and new election of Ann-Charlotte Jarleryd as Board members. Mikael Worning was also re-elected as the Chairman of the Board of Directors. The AGM resolved on new election of the audit firm KPMG AB as auditor.

Furthermore, the AGM resolved on remuneration to the Board of Directors, remuneration to the auditor and additional remuneration for work in the Board's committees in accordance with the Nomination committee's proposal.

Nomination committee for the next Annual General Meeting

The AGM resolved, in accordance with the Nomination committee's proposal, that the principles for appointing the Nomination committee which were adopted at the AGM in 2020 shall apply also for the AGM to be held in 2023.

Remuneration report

The AGM approved the Board of Directors' remuneration report for the financial year 2021.

Contact

Adele Horn Corporate Communications & Investor Relations Direct: +46 (0) 464 602 604 Mobile: +46 (0) 722 065 088

About Us

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 17 local market support organizations covering more than 40 countries. In 2021, sales were SEK 566 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www. cellavision.com

Attachments

Bulletin from the Annual General Meeting of CellaVision AB (publ)